Objective  To analyze the influence of minapulam and duloxetine on the therapeutic effect and cognitive function of patients with depression.

Methods  A retrospective analysis was conducted on the clinical data of patients with depression admitted to the Third People's Hospital of Huzhou City from January 2023 to December 2024. They were divided into the observation group (minapulam) and the control group (duloxetine) according to the medication. The therapeutic effects of the two groups were compared [evaluated based on the reduction rate of the Hamilton Depression Scale (HAMD) before and after treatment], HAMD before and after treatment, the score of the Clinical Efficacy Evaluation Scale (CGI), cognitive function, inflammatory factors [interleukin-6 (IL-6), interleukin-10 (IL^-10), tumor necrosis factor  -α (TNF-α)], norepinephrine (NE), 5-hydroxytryptamine (5-HT) and the occurrence of adverse reactions.

Results  A total of 118 patients were included, with 60 in the observation group and 58 in the control group. There was no statistically significant difference in the therapeutic effect between the two groups (P>0.05). After treatment, the HAMD and CGI scores of the two groups were lower than those before treatment (P<0.05), and the scores of the Mini-Mental State Examination (MMSE) and the Wisconsin Card Sorting Test (WCST) in both groups were higher than those before the treatment (P<0.05). After treatment, NE and 5-HT in both groups increased compared with those before treatment (P<0.05). After treatment, NE in the observation group was higher than that in the control group (P<0.05), while there was no statistically significant difference in 5-HT between the two groups (P>0.05). After the treatment, the levels of IL-6 and TNF-α in both groups were lower than those before the treatment, and the level of IL-10 was higher than that before the treatment (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05).

Conclusion  The efficacy of minapulam and duloxetine in the treatment of depression is comparable. Both can improve the cognitive function of patients. Minapulam has a significant anti-inflammatory effect and higher safety.

1.丁砚秋, 袁惠民, 陈潇, 等. 抑郁症的现代医学研究与治疗进展[J]. 西部医学, 2024, 36(4): 614-618. [Ding YQ, Yuan  HM, Chen X, et al. Progress in modern medical treatment of depression[J]. Medical Journal of West China, 2024, 36(4): 614-618.] DOI: 10.3969/j.issn.1672-3511.2024.04.028.

2.欧灿纯, 朱晓茜, 朱金芳. 度洛西汀、草酸艾司西酞普兰、米氮平治疗抑郁症的成本-效果分析[J]. 中国药师, 2015, 18(3): 449-451. [Ou CC, Zhu XQ, Zhu JF. Cost-effectiveness analysis of duloxetine, escitalopram oxalate and mirtazapine in the treatment of de-pression[J]. Chinese Pharmacists, 2015, 18(3): 449-451.] DOI: 10.3969/j.issn.1008-049X.2015.03.030.

3.丰雷, 朱雪泉, 王刚. 不同起始剂量米那普仑治疗抑郁症的有效性和安全性[J]. 中国新药与临床杂志, 2019, 38(2): 98-102. [Feng L, Zhu XQ, Wang G. Efficacy and safety of different initial doses of milnacipran in patients with major depressive disorder[J]. Chinese Journal of New Drugs and Clinical Remedies, 2019, 38(2): 98-102.] DOI: 10.14109/j.cnki.xyylc.2019.02.009.

4.姬彦彬, 王忠, 陈文浩, 等. 米那普仑治疗抑郁障碍的研究进展[J]. 中国药物依赖性杂志, 2020, 29(2): 93-100. [Ji  YB, Wang Z, Chen WH, et al. Research progress of milnacipran in treating depressive disorder[J]. Chinese Journal of Drug Dependence, 2020, 29(2): 93-100.] DOI: 10.13936/j.cnki.cjdd1992.2020.02.003.

5.周莉霞, 王学刚. 度洛西汀联合米氮平对合并躯体疼痛的抑郁症患者的效果[J]. 国际精神病学杂志, 2024, 51(4): 1137-1139. [Zhou LX, Wang XG. The effect of duloxetine combined with imirtazapine in depression patients with somatic pain[J]. Journal of International Psychiatry, 2024, 51(4): 1137-1139.] DOI: 10.13479/j.cnki.jip.2024.04.070.

6.美国精神医学学会. 编著. 美张道龙, 译. 精神障碍诊断与统计手册[M]. 北京: 北京大学出版社, 2015: 33-36.

7.金金, 何燕玲, 卓恺明, 等. 精神病症状维度评定量表中文版的效度和信度[J]. 中国心理卫生杂志, 2020, 34(11): 932-939. [Jin J, He YL, Zhuo KM, et al. Validity and reliability of the clinician-rated dimensions of psychosis symptom severity[J]. Chinese Mental Health Journal, 2020, 34(11): 932-939.] DOI: 10.3969/j.issn.1000-6729.2020.11.008.

8.郭蕊, 丁选胜, 张晋萍, 等. 三种量表对老年晚期癌症患者抑郁状态评估一致性比较[J]. 实用预防医学, 2019, 26(6): 762-765. [Guo R, Ding XS, Zhang JP, et al. Comparison of the consistency of three scales in evaluating depression status in elderly patients with advanced cancer[J]. Practical Preventive Medicine, 2019, 26(6): 762-765.] DOI: 10.3969/j.issn.1006-3110.2019.06.037.

9.周小炫, 谢敏, 陶静, 等. 简易智能精神状态检查量表的研究和应用[J]. 中国康复医学杂志, 2016, 31(6): 694-696. [Zhou XX, Xie M, Tao J, et al. Research and application of the mini-mental state examination scale[J]. Chinese Journal of Rehabilitation Medicine, 2016, 31(6): 694-696.] DOI: 10.3969/j.issn.1001-1242.2016.06.019.

10.谭云龙, 邹义壮, 屈英, 等. 威斯康星卡片分类测验常用指标的稳定性分析[J]. 中国心理卫生杂志, 2002, 16(12): 831-833. [Tan YL, Zou YZ, Qu Y, et al. Stability of commonly used measures in the wisconsin card sorting test[J]. Chinese Mental Health Journal, 2002, 16(12): 831-833.] DOI: 10.3321/j.issn:1000-6729.2002.12.009.

11.荣健, 戈艳红, 孟娜娜, 等. 2010—2019年中国老年人抑郁症患病率的Meta分析[J]. 中国循证医学杂志, 2020, 20(1): 26-31. [Rong J, Ge YH, Meng NN, et al. Prevalence rate of depression in Chinese elderly from 2010 to 2019: a meta-analysis[J]. Chinese Journal of Evidence-Based Medicine, 2020, 20(1): 26-31.] DOI: 10.7507/1672-2531.201908088.

12.路淑淑, 李文馨, 张贝贝, 等. 艾司西酞普兰与度洛西汀治疗抑郁症有效性与安全性的Meta分析[J]. 中国药房, 2018, 29(10): 1395-1400. [Lu SS, Li WX, Zhang BB, et al. Effectiveness and safety of escitalopram and duloxetine in the treatment of depression: a Meta-analysis[J]. Chinese Pharmacy, 2018, 29(10): 1395-1400.] DOI: 10.6039/j.issn.1001-0408.2018.10.25.

13.穆小梅, 牛慧明, 王秀梅, 等. 米那普仑与度洛西汀治疗伴有疼痛的老年抑郁症[J]. 临床精神医学杂志, 2023, 33(4): 303-306. [Mu XM, Niu HM, Wang XM, et al. Minapulun and duloxetine in the treatment of clinical depression in elderly with pain: a control study[J]. Journal of Clinical Psychiatry, 2023, 33(4): 303-306.] DOI: 10.3969/j.issn.1005-3220.2023.04.014.

14.Hitomi S, Yu O, Takayuki Y, et al. Noradrenaline reuptake inhibition increases control of impulsive action by activating D1-like receptors in the infralimbic cortex[J]. Eur J Pharmacol, 2018, 844(5): 17-25. DOI: 10.1016/j.ejphar.2018.11.041.

15.Keks NA, Hope J, Keogh S, et al. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant[J]. Australa Psychiatry, 2018, 26(5): 537-540. DOI: 10.1177/1039856218794874.

16.Kishi T, Ikuta T, Sakuma K, et al. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network Meta-analysis[J]. Mol Psychiatry, 2023, 28(1): 402-409. DOI: 10.1038/s41380-022-01824-z.

17.Gabriel FC, Melo DOD, Renerio F, et al. Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations[J]. PLoS One, 2020, 15(4): e0231700. DOI: 10.1371/journal.pone.0231700.

18.Gupta H, Girma B, Jenkins JS, et al. Milnacipran for the treatment of fibromyalgia[J]. Health Psychol Res, 2021, 9(1): 25532. DOI: 10.52965/001c.25532.

19.Kazuyuki N, Yuma Y, Atsuo N, et al. Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: a randomized, parallel-group, non-inferiority trial-ScienceDirect[J].J Affect Disorders, 2021, 282(1): 1011-1020. DOI: 10.1016/j.jad.2020.12.148.Epub 2021 Jan 5.

20.梁彦彬, 张俊, 田秋思, 等. 米那普仑联合认知行为疗法对轻型颅脑外伤后抑郁患者血清5-HT, BDNF及睡眠质量的影响[J]. 国际精神病学杂志, 2024, 51(2): 509-512. [Liang  YB, Zhang J, Tian QS, et al. Effects of minapram combined with cognitive behavioral therapy on serum 5-HT,BDNF and sleep quality in patients with depression after mild craniocerebral trauma[J]. Journal of International Psychiatry, 2024, 51(2): 509-512.] DOI: 10.13479/j.cnki.jip.2024.02.022.